Restoring Liver Health

Promethera’s mission is to bring patients life-saving treatments to reduce the need for liver transplantation.

 


Latest news

Promethera Biosciences is proud to announce that our CEO John Tchelingerian has been acknowledged by Global Business Awards 2019 for his leadership at Promethera!

The Global Business Awards are dedicated to the recognition of businesses, business owners and notable business leaders who continue to grow and develop their company – to stay ahead of the competition.

 


pti-diseases

Disease Focus

Promethera is pioneering the development of novel cell-based therapies for the treatment of a broad variety of liver diseases. The Company’s platform has the potential to deliver novel therapeutic options for inherited disorders including hemophilia as well as acquired chronic and acute liver diseases such as Acute-on-Chronic-Liver Failure (ACLF), fibrosis and Non-Alcoholic Steatohepatits (NASH).

pti-bars

Pipeline

Promethera’s most advanced cell-based therapy, HepaStem, is currently being evaluated in an open-label Phase 2a clinical trial to treat patients with Acute-on-Chronic-Liver Failure (ACLF). The program has the potential to target more prevalent chronic or progressive severe liver diseases such as Non-Alcoholic Steatohepatitis (NASH) and Fibrosis. Promethera has further strengthened its pipeline with complementary biologics, including the anti-TNF-R1 antibody Atrosimab.

pti-marker

International Presence

Promethera Biosciences is headquartered in Belgium's Walloon region, which is internationally known for excellence in cell therapy research. From here, the company has begun early on to establish a global footprint with a US subsidiary in Durham, North Carolina, a biologics unit in Basel, Switzerland and a Japanese branch office in Tokyo. Each site serves a specific function within the Promethera Group structure.


docs

Documents

All Documents
download

Corporate Presentation

Get a brief overview of Promethera's activities and view our latest corporate presentation.

download

Corporate Factsheet

Learn more about Promethera's activities and have a look at our Corporate Factsheet.  

investors-home-piechart.png

Since inception, Promethera Biosciences has raised EUR 80 million in equity and semi-equity from a broad range of leading European and Asian investors.

Promethera has outstanding capabilities and expertise in liver biology and cell-based medicine. These activities currently include the use of HepaStem in hemophilia and the Heparesc product line. More

Cell based delivery

Sign Up